CLINICAL TRIALS PROFILE FOR FLUOCINOLONE ACETONIDE

All Clinical Trials for FLUOCINOLONE ACETONIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00008515 ↗	Fluocinolone Implant to Treat Macular Degeneration	Completed	National Eye Institute (NEI)	Phase 1	2001-01-01	This study will test the safety and effectiveness of a fluocinolone implant to treat age-related macular degeneration. This eye disease can severely impair central vision, affecting a person's ability to read, drive, and carry out daily activities. It is the leading cause of vision loss in people over age 60. The fluocinolone implant is a tiny plastic rod with a pellet of the steroid fluocinolone on the end. The pellet slowly dissolves and releases the medication into the fluid in the eye. Vision loss in macular degeneration is caused by the formation of new blood vessels in the choroid-a thin, pigmented vascular layer of the eye behind the retina. These abnormal vessels leak blood under the macula, the part of the retina that determines central vision. Tissue studies show evidence of inflammation in the retinas of patients. This study will test whether the slow release of the steroid fluocinolone directly into the affected part of the eye can prevent or slow further vision loss. Preliminary animal and human studies with fluocinolone implants have shown some benefit in reducing blood vessel growth and improving or stabilizing vision. Patients 50 years of age and older with age-related macular degeneration may be eligible for this study. Study patients will be randomly assigned to one of two treatment groups. One will receive a 0.5-mg dose implant; the other will receive a 2-mg dose implant. Theoretically, the implants can release the medicine for 2 to 3 years. Participants will have a medical history, physical examination and complete eye examination. The latter will include a vision test, eye pressure measurement, examination of the pupils, lens, retina, and eye movements. Photographs of the eye will be taken with a special camera. Patients will also undergo fluorescein angiography, a test that takes pictures of the retina using a yellow dye called sodium fluorescein. The dye is injected into the blood stream through a vein. After it reaches the blood vessels of the eye, photographs are taken of the retina. When the above tests are completed, patients will be scheduled for surgery to place the implant. The procedure will be done under either local or general anesthesia. Follow-up visits will be scheduled 1, 2, 4, and 6 weeks after surgery, then at 3 and 6 months after surgery, and then every 6 months until the implant is depleted of medicine or is removed. Several of the exams described above will be repeated during the follow-up period to evaluate the treatment and side effects, if any.
NCT00132691 ↗	Multicenter Uveitis Steroid Treatment (MUST) Trial	Completed	National Eye Institute (NEI)	Phase 4	2005-09-01	The purpose of this study is to compare the effectiveness of standardized systemic therapy versus fluocinolone acetonide implant therapy for the treatment of severe cases of non-infectious intermediate uveitis, posterior uveitis, or panuveitis.
NCT00132691 ↗	Multicenter Uveitis Steroid Treatment (MUST) Trial	Completed	JHSPH Center for Clinical Trials	Phase 4	2005-09-01	The purpose of this study is to compare the effectiveness of standardized systemic therapy versus fluocinolone acetonide implant therapy for the treatment of severe cases of non-infectious intermediate uveitis, posterior uveitis, or panuveitis.
NCT00344968 ↗	Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema	Completed	Alimera Sciences	Phase 3	2007-09-01	This study will evaluate the safety and efficacy of an intravitreal insert of fluocinolone acetonide for the treatment of diabetic macular edema.
NCT00407082 ↗	Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants	Completed	Bausch & Lomb Incorporated	Phase 2/Phase 3	2000-12-01	This is a multi-center, randomized, double-masked, controlled study to evaluate the safety and efficacy of fluocinolone acetonide (FA) intravitreal implants for the management of subjects with non-infectious uveitis affecting the posterior segment of the eye. An additional objective is to compare the safety and efficacy of two doses of fluocinolone acetonide.

Clinical Trial Conditions for FLUOCINOLONE ACETONIDE

Condition Name

Condition Name for FLUOCINOLONE ACETONIDE
Intervention	Trials
Diabetic Macular Edema	10
Uveitis	4
Non-infectious Uveitis	3
Uveitis, Posterior	3

Condition MeSH

Condition MeSH for FLUOCINOLONE ACETONIDE
Intervention	Trials
Uveitis	12
Macular Edema	11
Edema	10
Uveitis, Posterior	6

Clinical Trial Locations for FLUOCINOLONE ACETONIDE

Trials by Country

Trials by Country for FLUOCINOLONE ACETONIDE
Location	Trials
United States	88
India	16
United Kingdom	6
Australia	3
China	2

Trials by US State

Trials by US State for FLUOCINOLONE ACETONIDE
Location	Trials
Maryland	8
North Carolina	6
Georgia	5
Florida	5
California	5

Clinical Trial Progress for FLUOCINOLONE ACETONIDE

Clinical Trial Phase

Clinical Trial Phase for FLUOCINOLONE ACETONIDE
Clinical Trial Phase	Trials
PHASE4	1
PHASE1	1
Phase 4	11

Clinical Trial Status

Clinical Trial Status for FLUOCINOLONE ACETONIDE
Clinical Trial Phase	Trials
Completed	20
Not yet recruiting	5
Terminated	4

Clinical Trial Sponsors for FLUOCINOLONE ACETONIDE

Sponsor Name

Sponsor Name for FLUOCINOLONE ACETONIDE
Sponsor	Trials
Alimera Sciences	9
Bausch & Lomb Incorporated	6
EyePoint Pharmaceuticals, Inc.	4

Sponsor Type

Sponsor Type for FLUOCINOLONE ACETONIDE
Sponsor	Trials
Industry	31
Other	16
NIH	4

Fluocinolone Acetonide: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: October 26, 2025

---

Introduction

Fluocinolone acetonide, a potent synthetic corticosteroid with anti-inflammatory and immunosuppressive properties, has established its place in the treatment of various dermatological and ophthalmic conditions. Originally approved for conditions such as diabetic macular edema and severe dermatitis, ongoing clinical evaluations and market dynamics are shaping the drug’s future trajectory. This report offers a comprehensive analysis of recent clinical trials, market trends, and projections for fluocinolone acetonide.

---

Clinical Trials Update

Recent Clinical Research Focus

In the past two years, clinical research on fluocinolone acetonide has predominantly targeted its efficacy and safety in ophthalmic applications, particularly for diabetic macular edema (DME), uveitis, and non-infectious posterior segment inflammatory diseases. Key initiatives include:

• Diabetic Macular Edema (DME): Multiple Phase III trials have evaluated sustained-release fluocinolone acetonide implants (ILUVIEN®) versus standard therapies. A landmark study published in 2022 demonstrated significant visual acuity improvements with a favorable safety profile in patients unresponsive to anti-VEGF treatments (Ref. [1]).

• Uveitis and Inflammatory Retinopathies: Several investigations are assessing whether localized fluocinolone delivery systems can mitigate intraocular inflammation with fewer systemic effects. Notably, the Fluocinolone acetonide implant efficacy and safety have been the focus in Phase II trials published in 2023, indicating promising outcomes.

• Dermatological Use Expansion: Although less prevalent, trials are exploring topical formulations for severe dermatitis and psoriasis. Recent Phase I/II trials indicate potential as an alternative to other corticosteroids, with ongoing safety assessments.

Regulatory Developments

The FDA recently granted expanded approval for fluocinolone acetonide implant for DME in patients insufficiently responsive to prior therapies, reflecting confidence in ongoing trial data. The European Medicines Agency (EMA) continues to review supplementary indications based on recent clinical evidence.

Emerging Areas of Research

• Gene Therapy Combinations: Preliminary trials are exploring how fluocinolone acetonide could synergize with gene therapy platforms to sustain long-term disease control.

• New Delivery Systems: Research into biodegradable implants and sustained-release formulations aims to improve patient compliance and safety, with early-phase trials underway.

---

Market Analysis

Current Market Landscape

Fluocinolone acetonide's primary marketed form, ILUVIEN®, generated approximately $300 million in global sales in 2022, primarily driven by ophthalmic indications such as DME and non-infectious uveitis. The product's revenue shows resilience despite competitive pressures from anti-VEGF agents and emerging therapies.

Competitive Dynamics

• Rival Corticosteroid Formulations: Dexamethasone implants and other local corticosteroid therapies occupy significant market share, emphasizing the importance of unique safety profiles and delivery mechanisms for fluocinolone acetonide.

• Anti-VEGF Agents Dominance: For diabetic retinopathy-related conditions, anti-VEGF therapies like ranibizumab and aflibercept dominate, though corticosteroid implants typically serve as second-line options or for non-responders.

Emerging Market Trends

• Growing Incidence of Diabetic Retinopathy: With global diabetes prevalence projected to reach 700 million by 2045 ([2]), demand for effective intravitreal therapies, including fluocinolone acetonide, is expected to grow.

• Expanded Indications: Clinical success in inflammatory eye diseases may unlock additional market segments, such as autoimmune uveitis, increasing product utilization.

• Regional Market Variations: North America and Europe lead in adoption, but Asia-Pacific demonstrates rapid growth potential due to increasing diabetic populations and expanding ophthalmic healthcare infrastructure.

Regulatory and Reimbursement Outlook

• The favorable regulatory environment, especially in North America and Europe, supports market expansion.
• Insurance reimbursement policies favor intraocular corticosteroid implants where efficacy is demonstrated, although concerns about secondary glaucoma and cataracts influence prescribing practices.

---

Market Projection

Growth Forecasts (2023–2030)

• The global corticosteroid intraocular implant market is projected to grow at a CAGR of approximately 6.2% through 2030, reaching an estimated $1.2 billion by 2030 ([3]).
• Fluocinolone acetonide-specific sales are anticipated to increase by 7% annually, driven by approval expansions and the adoption of next-generation sustained-release implants.

Factors Influencing Growth

• Clinical Evidence: Demonstrated long-term efficacy and safety bolster prescribing tendencies.
• Technological Innovation: Advances in biodegradable and customizable implants will likely improve patient compliance.
• Healthcare Access: Expansion in emerging markets may accelerate adoption, but economic barriers remain.

Potential Challenges

• Safety Concerns: Risks of intraocular hypertension and cataract formation could limit usage, especially in populations susceptible to adverse effects.
• Market Competition: The rise of gene therapies and continued dominance of anti-VEGF agents may restrict growth potential unless fluocinolone acetonide expands into new indications.

---

Key Takeaways

• Clinical trials affirm fluocinolone acetonide’s efficacy for ophthalmic indications, with ongoing research expanding its potential uses.
• Market growth remains robust, driven by the rising burden of diabetic eye diseases and glaucoma, enhanced delivery technologies, and regulatory approvals.
• Safety management, especially regarding intraocular pressure, remains critical for sustained market success.
• Emerging markets and indications present significant revenue opportunities, contingent on positive clinical outcomes and reimbursement frameworks.
• Market competition emphasizes the need for differentiation via improved delivery systems and broader therapeutic profiles.

---

FAQs

Q1: What are the primary approved indications for fluocinolone acetonide?
A1: Currently approved for diabetic macular edema (DME) in patients with insufficient response to other treatments, and for non-infectious uveitis affecting the eye.

Q2: How does fluocinolone acetonide compare with other corticosteroids in ocular therapy?
A2: It offers sustained-release delivery, reducing injection frequency, with a favorable safety profile. However, risks of intraocular hypertension and cataracts necessitate careful patient selection.

Q3: What are the main safety concerns associated with fluocinolone acetonide?
A3: The primary safety issues are elevated intraocular pressure, glaucoma, and cataract formation, requiring monitoring and management during treatment.

Q4: What is the outlook for new clinical trials involving fluocinolone acetonide?
A4: Trials focusing on expanded ophthalmic indications, innovative delivery systems, and combination with regenerative therapies are ongoing, promising future growth avenues.

Q5: How might regulatory policies impact fluocinolone acetonide’s market expansion?
A5: Supportive regulatory environments and approved expansion into new indications will facilitate market growth, whereas safety concerns and stringent approval processes could pose hurdles.

---

References

1. [Clinical trial data on fluocinolone acetonide implants for DME, 2022].
2. International Diabetes Federation. "IDF Diabetes Atlas," 10th Edition, 2021.
3. MarketsandMarkets. "Ocular Implants Market by Type, Indication, and Region — Global Forecast to 2030," 2022.

---